Literature DB >> 17223013

Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia.

Robert E McCullumsmith1, Daya Gupta, Monica Beneyto, Emily Kreger, Vahram Haroutunian, Kenneth L Davis, James H Meador-Woodruff.   

Abstract

Several recent studies have found changes in the expression of genes functionally related to myelination and oligodendrocyte homeostasis in schizophrenia. These studies utilized microarrays and quantitative PCR (QPCR), methodologies which do not permit direct, unamplified examination of mRNA expression. In addition, these studies generally only examined transcript expression in homogenates of gray matter. In the present study, we examined the expression of myelination-related genes previously implicated in schizophrenia by microarray or QPCR. Using in situ hybridization, we measured transcript expression of 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), myelin-associated glycoprotein (MAG), transferrin (TF), quaking (QKI), gelsolin, myelin oligodendrocyte glycoprotein, v-erb-b2 erythroblastic leukemia viral oncogene homolog 3, erbb2 interacting protein, motility-related protein-1, SRY-box containing gene 10, oligodendrocyte transcription factor 2, peripheral myelin protein 22, and claudin-11 in both gray and white matter of the anterior cingulate cortex (ACC) in subjects with schizophrenia (n=41) and a comparison group (n=34). We found decreased expression of MAG, QKI, TF, and CNP transcripts in white matter. We did not find any differences in expression of these transcripts between medicated (n=31) and unmedicated (n=10) schizophrenics, suggesting that these changes are not secondary to treatment with antipsychotics. Finally, we found significant positive correlations between QKI and MAG or CNP mRNA expression, suggesting that the transcription factor QKI regulates MAG and CNP expression. Our results support the hypothesis that myelination and oligodendrocyte function are impaired in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17223013      PMCID: PMC1880890          DOI: 10.1016/j.schres.2006.11.017

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  61 in total

1.  Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia.

Authors:  K O Lim; E Adalsteinsson; D Spielman; E V Sullivan; M J Rosenbloom; A Pfefferbaum
Journal:  Arch Gen Psychiatry       Date:  1998-04

2.  Compromised white matter tract integrity in schizophrenia inferred from diffusion tensor imaging.

Authors:  K O Lim; M Hedehus; M Moseley; A de Crespigny; E V Sullivan; A Pfefferbaum
Journal:  Arch Gen Psychiatry       Date:  1999-04

Review 3.  Molecular defects in the dysmyelinating mutant quaking.

Authors:  R J Hardy
Journal:  J Neurosci Res       Date:  1998-02-15       Impact factor: 4.164

4.  MRI white matter diffusion anisotropy and PET metabolic rate in schizophrenia.

Authors:  M S Buchsbaum; C Y Tang; S Peled; H Gudbjartsson; D Lu; E A Hazlett; J Downhill; M Haznedar; J H Fallon; S W Atlas
Journal:  Neuroreport       Date:  1998-02-16       Impact factor: 1.837

5.  Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases.

Authors:  D P Purohit; D P Perl; V Haroutunian; P Powchik; M Davidson; K L Davis
Journal:  Arch Gen Psychiatry       Date:  1998-03

6.  Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins.

Authors:  S W Flynn; D J Lang; A L Mackay; V Goghari; I M Vavasour; K P Whittall; G N Smith; V Arango; J J Mann; A J Dwork; P Falkai; W G Honer
Journal:  Mol Psychiatry       Date:  2003-09       Impact factor: 15.992

7.  Transferrin is an essential factor for myelination.

Authors:  A Espinosa de los Monteros; S Kumar; P Zhao; C J Huang; R Nazarian; T Pan; S Scully; R Chang; J de Vellis
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

8.  Oligodendrocyte dysfunction in schizophrenia and bipolar disorder.

Authors:  Dmitri Tkachev; Michael L Mimmack; Margaret M Ryan; Matt Wayland; Tom Freeman; Peter B Jones; Michael Starkey; Maree J Webster; Robert H Yolken; Sabine Bahn
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

9.  Severity of symptoms in chronically institutionalized geriatric schizophrenic patients.

Authors:  M Davidson; P D Harvey; P Powchik; M Parrella; L White; H Y Knobler; M F Losonczy; R S Keefe; S Katz; E Frecska
Journal:  Am J Psychiatry       Date:  1995-02       Impact factor: 18.112

10.  Expression of myelin basic protein mRNA and polypeptides in mouse oligodendrocytes in culture: differential regulation by genetic and epigenetic factors.

Authors:  E Barbarese; C Barry; C D'Occhio; S Edgar; A Akowitz; J H Carson
Journal:  Brain Res       Date:  1988-04-01       Impact factor: 3.252

View more
  53 in total

1.  Oligodendrocyte genes, white matter tract integrity, and cognition in schizophrenia.

Authors:  Aristotle N Voineskos; Daniel Felsky; Natasa Kovacevic; Arun K Tiwari; Clement Zai; M Mallar Chakravarty; Nancy J Lobaugh; Martha E Shenton; Tarek K Rajji; Dielle Miranda; Bruce G Pollock; Benoit H Mulsant; Anthony R McIntosh; James L Kennedy
Journal:  Cereb Cortex       Date:  2012-07-06       Impact factor: 5.357

2.  A combined diffusion tensor imaging and magnetic resonance spectroscopy study of patients with schizophrenia.

Authors:  Meredith A Reid; David M White; Nina V Kraguljac; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2015-12-21       Impact factor: 4.939

3.  Decreased protein S-palmitoylation in dorsolateral prefrontal cortex in schizophrenia.

Authors:  Anita L Pinner; Janusz Tucholski; Vahram Haroutunian; Robert E McCullumsmith; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2016-02-11       Impact factor: 4.939

Review 4.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

5.  Expression of oligodendrocyte-associated genes in dorsolateral prefrontal cortex of patients with schizophrenia.

Authors:  Shruti N Mitkus; Thomas M Hyde; Radhakrishna Vakkalanka; Bhaskar Kolachana; Daniel R Weinberger; Joel E Kleinman; Barbara K Lipska
Journal:  Schizophr Res       Date:  2007-10-26       Impact factor: 4.939

6.  Expression of transcripts for myelin related genes in postmortem brain from cocaine abusers.

Authors:  Lars V Kristiansen; Michael J Bannon; James H Meador-Woodruff
Journal:  Neurochem Res       Date:  2008-03-21       Impact factor: 3.996

Review 7.  Better understanding of mechanisms of schizophrenia and bipolar disorder: from human gene expression profiles to mouse models.

Authors:  Chi-Ying Lin; Akira Sawa; Hanna Jaaro-Peled
Journal:  Neurobiol Dis       Date:  2011-09-03       Impact factor: 5.996

8.  Ethnicity-Dependent Effects of Schizophrenia Risk Variants of the OLIG2 Gene on OLIG2 Transcription and White Matter Integrity.

Authors:  Hiroshi Komatsu; Hikaru Takeuchi; Yoshie Kikuchi; Chiaki Ono; Zhiqian Yu; Kunio Iizuka; Yuji Takano; Yoshihisa Kakuto; Shunichi Funakoshi; Takashi Ono; Junko Ito; Yasuto Kunii; Mizuki Hino; Atsuko Nagaoka; Yasushi Iwasaki; Hidenaga Yamamori; Yuka Yasuda; Michiko Fujimoto; Hirotsugu Azechi; Noriko Kudo; Ryota Hashimoto; Hirooki Yabe; Mari Yoshida; Yuko Saito; Akiyoshi Kakita; Nobuo Fuse; Ryuta Kawashima; Yasuyuki Taki; Hiroaki Tomita
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

9.  High novelty-seeking rats are resilient to negative physiological effects of the early life stress.

Authors:  Sarah M Clinton; Stanley J Watson; Huda Akil
Journal:  Stress       Date:  2013-11-06       Impact factor: 3.493

10.  Evidence for morphological alterations in prefrontal white matter glia in schizophrenia and bipolar disorder.

Authors:  Christa Hercher; Vikramjit Chopra; Clare L Beasley
Journal:  J Psychiatry Neurosci       Date:  2014-11       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.